Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart Elborn

Showing results (41-50 of 325) with videos related to

Pageof 33
Sort By:
Thorax|October 29, 2015
Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and BarryJ Stuart Elborn, Bonnie Ramsey, Claire Wainwright, et al.
The New England Journal of Medicine|October 29, 2015
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTRClaire E Wainwright, J Stuart Elborn, Bonnie W Ramsey
Lancet (London, England)|August 26, 2014
Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosisLaura J Sherrard, Michael M Tunney, J Stuart Elborn
The New England Journal of Medicine|March 26, 2026
Hypertonic Saline or Carbocisteine in Bronchiectasis. ReplyJudy M Bradley, Daniel F McAuley, J Stuart Elborn
The Lancet. Respiratory Medicine|January 17, 2014
A new Clinical Trials Directive to boost academic trials?Kris De Boeck, Harm Tiddens, Stuart Elborn, et al.
Chest|August 13, 2011
Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosaMichael D Parkins, Jacqueline C Rendall, J Stuart Elborn
American Journal of Respiratory and Critical Care Medicine|May 3, 2014
Reply: lung clearance index in primary ciliary dyskinesia and bronchiectasisStephen Rowan, Alex Horsley, Judy Bradley, et al.
Cold Spring Harbor Perspectives in Medicine|July 25, 2013
Antibiotic and anti-inflammatory therapies for cystic fibrosisJames F Chmiel, Michael W Konstan, J Stuart Elborn
Presse Medicale (Paris, France : 1983)|May 31, 2017
Current and emerging comorbidities in cystic fibrosisNicola J Ronan, Joseph Stuart Elborn, Barry J Plant
International Immunopharmacology|February 3, 2005
Effect of cystic fibrosis exacerbations on neutrophil functionSimon Brockbank, Damian Downey, J Stuart Elborn, et al.
Pageof 33

Showing results (41-50 of 325) with videos related to

Sort By:
Pageof 33
Thorax|October 29, 2015
Response to: 'Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?' by Jones and BarryJ Stuart Elborn, Bonnie Ramsey, Claire Wainwright, et al.
The New England Journal of Medicine|October 29, 2015
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTRClaire E Wainwright, J Stuart Elborn, Bonnie W Ramsey
Lancet (London, England)|August 26, 2014
Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosisLaura J Sherrard, Michael M Tunney, J Stuart Elborn
The New England Journal of Medicine|March 26, 2026
Hypertonic Saline or Carbocisteine in Bronchiectasis. ReplyJudy M Bradley, Daniel F McAuley, J Stuart Elborn
The Lancet. Respiratory Medicine|January 17, 2014
A new Clinical Trials Directive to boost academic trials?Kris De Boeck, Harm Tiddens, Stuart Elborn, et al.
Chest|August 13, 2011
Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosaMichael D Parkins, Jacqueline C Rendall, J Stuart Elborn
American Journal of Respiratory and Critical Care Medicine|May 3, 2014
Reply: lung clearance index in primary ciliary dyskinesia and bronchiectasisStephen Rowan, Alex Horsley, Judy Bradley, et al.
Cold Spring Harbor Perspectives in Medicine|July 25, 2013
Antibiotic and anti-inflammatory therapies for cystic fibrosisJames F Chmiel, Michael W Konstan, J Stuart Elborn
Presse Medicale (Paris, France : 1983)|May 31, 2017
Current and emerging comorbidities in cystic fibrosisNicola J Ronan, Joseph Stuart Elborn, Barry J Plant
International Immunopharmacology|February 3, 2005
Effect of cystic fibrosis exacerbations on neutrophil functionSimon Brockbank, Damian Downey, J Stuart Elborn, et al.
Pageof 33